Formylated chemotactic peptides, with endogenous Tc-99m binding sites, will be developed for use in localizing abscesses, inflammations, and infections. The peptides are designed to have the biological function located at one end of the molecule, and the Tc-99m binding site at the other end of the molecule. In Phase I the chemotactic peptide analogs will be formulated in single-step, direct labeling kits, and used in animal studies to localize infections and inflammations. Initial studies will include analysis of labeling efficiency and definition of optimal labeling conditions, and binding of Tc-99m-labeled formyl peptides to lymphocytes. In Phase II, comparative localization studies will be conducted, using In- 111-oxine-labeled lymphocytes and Tc-99m-human gamma globulin as reference materials.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43AI033276-01
Application #
3489666
Study Section
Special Emphasis Panel (SSS (B8))
Project Start
1992-09-01
Project End
1993-03-31
Budget Start
1992-09-01
Budget End
1993-03-31
Support Year
1
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Palatin Technologies, Inc.
Department
Type
DUNS #
City
Cranbury
State
NM
Country
United States
Zip Code
Zamora, P O; Domalewski, M D; Marek, M J et al. (1994) Quantitation of radiolabeled antibody binding to cells by thin-layer chromatography. Nucl Med Biol 21:205-10